Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082762 | 0.76 | NPC1 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1126619 | 0.68 | — | — | |
| Methoxymethane SCHEMBL27908243 | 0.67 | RAB9A (0.50) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7387155 | 0.67 | ALDH1A1 (0.35) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28934089 | 0.66 | — | — | |
| SCHEMBL970674 | 0.65 | KDM4E (0.56) | CYP1A2CYP19A1CYP2C9CYP2C19NPC1 | |
| SCHEMBL2675050 | 0.65 | KDM4E (0.43) | CYP19A1NPC1RAB9AKDM4E | |
| SCHEMBL718110 | 0.65 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1638199 | 0.65 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27774669 | 0.65 | NPC1 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466678-B | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH CORP | 2012-12-26 | — | — | CN | claimed |
| CN-102485743-A | Antineoplastic compound | BEIJING HANMEI PHARMACEUTICAL CO LTD | 2012-06-06 | — | — | CN | claimed |
| CN-101779124-A | modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC | 2010-07-14 | — | — | CN | claimed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | claimed |
| CN-1802348-A | Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof | COUNCIL SCIENT IND RES (IN) | 2006-07-12 | — | — | CN | claimed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| CN-1578660-A | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | CN | claimed |
| EP-0983272-B1 | A NEW CLASS OF BENZOPORPHYRIN DERIVATIVE PHOTOACTIVE COMPOUNDS | UNIV BRITISH COLUMBIA (CA) | 2003-10-29 | — | — | EP | claimed |
| CN-1120166-C | New class of benzoporphyrin derivative photoactive compounds | UNIV BRITISH COLUMBIA (CA) | 2003-09-03 | — | — | CN | claimed |
| CN-1255135-A | New class of benzoporphyrin derivative photoactive compounds | UNIV BRITISH COLUMBIA (CA) | 2000-05-31 | — | — | CN | claimed |
| CN-1138332-A | Pyridazinoquinoline compounds | ZENECA LTD (GB) | 1996-12-18 | — | — | CN | claimed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| CN-103508961-B | Antitumor drug | CROWN BIOSCIENCE TAICANG CO LTD | 2015-07-22 | — | — | CN | disclosed |
| CN-103508961-A | Antitumor drug | CROWN BIOSCIENCE TAICANG CO LTD | 2014-01-15 | — | — | CN | disclosed |
| CN-1151400-A | Novel sulfonylaminopyrimidines | HOFFMANN LA ROCHE (CH) | 1997-06-11 | — | — | CN | disclosed |
| CN-1138332-A | Pyridazinoquinoline compounds | ZENECA LTD (GB) | 1996-12-18 | — | — | CN | disclosed |
| EP-0630370-A1 | FUNGICIDAL OXAZOLIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993018016-A1 | FUNGICIDAL OXAZOLIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | CYP1A2 8/4885CYP2D6 31/4885CYP19A1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.